 Protein biomarker panels are becoming increasingly important in clinical medicine, as they provide a more comprehensive representation of human physiology compared to single protein biomarkers. This makes them ideal for improving diagnosis, prognosis and the differentiation of responders from non-responders in the context of precision medicine. However, despite the promise of these panels, their implementation into clinical practice has been limited due to various challenges. To address these challenges, it is essential to integrate proteomics into clinical routines by identifying the most promising panels, and implementing them in clinical settings. Targeted mass spectrometry is the most promising technology for achieving this goal due to its high flexibility, low sample costs, independence from affinity reagents and low entry barriers for integration into existing laboratory workflows. This article was authored by Johannes Hartl, Florian Kroth, Kaikaput, and others.